Saint Louis University Center for Health Outcomes Research, St. Louis, MO
Eric Adjei Boakye , Wiley D Jenkins , Nosayaba Osazuwa-Peters , Maggie Wang , Min Jee Lee , Betty Chen , Edem S. Agamah , Arun Sharma
Background: The number of cancer survivors in the United States is projected to exceed 20 million by 2024. Survivors are at risk of developing a second primary neoplasm (SPN) – a leading cause of survivor death. We described the risk of developing a SPN among survivors of common cancers (smoking-related vs non-smoking-related) in the United States. Methods: We identified patients aged ≥18 years who were diagnosed with a primary cancer from the 10 sites with highest survival rates and stratified as smoking-related (urinary bladder, kidney & renal pelvis, uterine cervix, oral cavity & pharynx, and colon & rectum) and non-smoking related (prostate, thyroid, breast, corpus & uterus, and non-Hodgkin lymphoma) from Surveillance, Epidemiology, and End Results (2000-2015). SPN was defined as the first subsequent primary cancer occurring ≥2 months after first cancer diagnosis. Excess SPN risk was quantified using standardized incidence ratios (SIRs) stratified by sex. Results: A cohort of 2,908,349 patients (50.1% female) was identified and 260,267 (9.0%) developed SPN (7.6% of females and 10.3% of males). All index cancer sites were associated with a significant increase in SPN risk for females and males (except prostate cancer). Index smoking-related cancers (SIR range 1.20 – 2.17 for females and 1.12 – 1.91 for males) had higher increased risk of SPN than non-smoking-related cancers (SIR range 1.08 – 1.39 for females and 0.55 – 1.38 for males) relative to the general population. Conclusions: Nearly 10% of cancer survivors developed an SPN, and those with smoking-related cancers had higher risk. Given the increasing number of cancer survivors and importance of SPN as a cause of cancer death, these findings can improve secondary prevention and surveillance guidelines.
Men | Women | ||||
---|---|---|---|---|---|
Index cancer | Observed SPN | SIR (95% CI) | Index cancer | Observed SPN | SIR (95% CI) |
Smoking-Related | Smoking-Related | ||||
Urinary bladder | 25,211 | 1.77 (1.75, 1.79) | Urinary bladder | 5,283 | 1.65 (1.60, 1.69) |
Kidney & renal pelvis | 9,461 | 1.53 (1.50, 1.56) | Kidney & renal pelvis | 4,448 | 1.50 (1.45, 1.54) |
Oral cavity and pharynx | 9,077 | 1.91 (1.87, 1.95) | Uterine cervix | 2,488 | 1.50 (1.44, 1.56) |
Colon & rectum | 21,375 | 1.12 (1.11, 1.14) | Oral cavity and pharynx | 3,444 | 2.17 (2.10, 2.24) |
Non-Smoking-Related | Colon & rectum | 15,825 | 1.20 (1.18, 1.22) | ||
Prostate | 71,866 | 0.65 (0.65, 0.66) | Non-Smoking-Related | ||
Thyroid | 1,722 | 1.23 (1.18, 1.29) | Thyroid | 3,730 | 1.12 (1.08, 1.16) |
Non-Hodgkin lymphoma | 10,011 | 1.38 (1.36, 1.41) | Breast | 56,725 | 1.17 (1.16, 1.18) |
Corpus & uterus, NOS | 10,131 | 1.08 (1.06, 1.10) | |||
Non-Hodgkin lymphoma | 7,239 | 1.39 (1.36, 1.42) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Callie Fort
2022 ASCO Gastrointestinal Cancers Symposium
First Author: Andreas Teufel
2022 ASCO Annual Meeting
First Author: Xinwen Hu
2023 ASCO Annual Meeting
First Author: Amanda Janitz